image: Modulating the activity of B and T cells improved pneumonitis in patients with APECED after one month (middle panel) and six months (right panel) of treatment. This material relates to a paper that appeared in the Jun. 5, 2019, issue of Science Translational Medicine, published by AAAS. The paper, by E. Ferré at National Institute of Allergy and Infectious Diseases (NIAID), NIH in Bethesda, MD; and colleagues was titled, "Lymphocyte-driven regional immunopathology in pneumonitis that is caused by impaired central immune tolerance." view more
Credit: E. Ferré <i>et al., Science Translational Medicine</i> (2019)